Professor, Immunobiology, Yale University School of Medicine
Endocrinology
Dr. Kevan C. Herold, MD
|
|
Give Review
Kevan Herold practices Endocrinology. He researched medicine at Jefferson Medical College. Kevan C. Herold has written publications. He has 101 publications published with PubMed. The lastest publication is: 'Endocrinology research-reflecting on the past decade and looking to the next.' He accepts Medicare.
Publications
- Endocrinology research-reflecting on the past decade and looking to the next.
- Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy.
- The Development and Utility of a Novel Scale That Quantifies the Glycemic Progression Toward Type 1 Diabetes Over 6 Months.
- Thinking bedside at the bench: the NOD mouse model of T1DM.
- A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History.
- Analysis of β-Cell Death in Type 1 Diabetes by Droplet Digital PCR.
- Humanized Mice as a Model for Aberrant Responses in Human T Cell Immunotherapy.
- Biomarkers in type 1 Diabetes: application to the clinical trial setting.
- Treatment of new onset type 1 Diabetes with teplizumab : successes and pitfalls in development.
- Characterization of residual β cell function in long-standing type 1 Diabetes.
- Anti-CD3 clinical trials in type 1 Diabetes mellitus.
- Restoring immune balance in type 1 Diabetes.
- Teplizumab preserves C-peptide in recent-onset type 1 Diabetes: two-year results from the randomized, placebo-controlled Protégé trial.
- Delayed anti-CD3 therapy in a mouse heart transplant model induced tolerance and long-term survival of allograft: achieving tolerance.
- Acute metabolic effects of exenatide in patients with Type 1 Diabetes with and without residual insulin to oral and IV glucose challenges.
- The Acceleration of the Loss of the First-Phase Insulin Response during the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants.
- Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 Diabetes in a randomized controlled trial: Metabolic and immunologi...
- Interleukin-1 antagonism in type 1 Diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
- Type 1 Diabetes: translating mechanistic observations into effective clinical outcomes.
- Novel SIRT1 Mutation Linked to Autoimmune Diabetes in Humans.
- Transient B-Cell Depletion With Anti-CD20 in Combination With Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice.
- Immune Therapy and β-Cell Death in Type 1 Diabetes.
- Teplizumab treatment may improve C-peptide responses in participants with type 1 Diabetes after the new-onset period: a randomised controlled trial.
- Relapsing and Remitting Severe Hypoglycemia due to a Monoclonal Anti-insulin Antibody Heralding a Case of Multiple Myeloma.
- Analysis of human biologics With a mouse skin transplant model in humanized mice.
- Immunologic and Metabolic Biomarkers of β-Cell Destruction in the Diagnosis of Type 1 Diabetes.
- In vivo imaging of endogenous pancreatic β-cell mass in healthy and Type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET.
- RAGE Expression in Human T Cells: A Link between Environmental Factors and Adaptive Immune Responses.
- Detection of ? cell death in Diabetes using differentially methylated circulating DNA.
- Synergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleukin-1 Blockade: Evidence of Improved Immune Regulation.
- Type 1 Diabetes immunotherapy: is the glass half empty or half full?
- How does type 1 Diabetes develop?: the notion of homicide or β-cell suicide revisited.
- NKG2A is a marker for acquisition of regulatory function by human CD8(+) T cells activated With anti-CD3 antibody.
- Glucose and inflammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by gluc...
- Immunotherapy of type 1 Diabetes: where are we and where should we be going?
- Monitoring of antigen-specific CD8 T cells in patients with type 1 Diabetes treated with antiCD3 monoclonal antibodies.
- Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-s...
- Remission of type 1 Diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors.
- Advances in Type 1 Diabetes therapeutics: immunomodulation and beta-cell salvage.
- Promotion of beta-cell differentiation in pancreatic precursor cells by adult islet cells.
- Human regulatory CD8 T cells.
- Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala).
- Beta-cell mass and type 1 Diabetes: going, going, gone?
- RAGE ligation affects T cell activation and controls T cell differentiation.
- A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene.
- Exendin-4 improves reversal of Diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.
- Autoimmunity and beta cell regeneration in mouse and human type 1 Diabetes: the peace is not enough.
- Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 Diabetes.
- Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 Diabetes: results of a blinded controlled study.
- Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune Diabetes by inducing Tregs.
- Patterns of metabolic progression to type 1 Diabetes in the Diabetes Prevention Trial-Type 1.
- Receptor for advanced glycation end products and its ligands: initiators or amplifiers of joint inflammation--a bit of both?
- Natural history of beta-cell function in type 1 Diabetes.
- TCR stimulation With modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.
- Achieving antigen-specific tolerance in Diabetes: regulating specifically.
- A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after o...
- Regulatory T cells and type 1 Diabetes.
- Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 Diabetes.
- Continuous subcutaneous insulin infusion in older patients with type 1 Diabetes.
- Treatment of type 1 Diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation.
- Blockade of late stages of autoimmune Diabetes by inhibition of the receptor for advanced glycation end products.
- Treatment of type 1 Diabetes mellitus to preserve insulin secretion.
- Achieving antigen-specific immune regulation.
- Insulin secretion in type 1 Diabetes.
- C-peptide is the appropriate outcome measure for type 1 Diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.
- Treatment of type 1 Diabetes with anti-CD3 monoclonal antibody.
- Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).
- Treatment of Type 1 Diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?
- Anti-CD3 monoclonal antibody in new-onset type 1 Diabetes mellitus.
- Pancreatic islets activate portal vein endothelial cells in vitro.
- Effect of rituximab on human in vivo antibody immune responses.
- Functional human to mouse adipose tissue xenotransplantation.
- Acquisition of regulatory function by human CD8(+) T cells treated With anti-CD3 antibody requires TNF.
- The role of AIRE in human autoimmune disease.
- Prevention of T1DM: feeding the ultimate goal.
- Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 Diabetes.
- Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 Diabetes: a randomised double-blind trial.
- Teplizumab for treatment of type 1 Diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
- Control of TH17 cells occurs in the small intestine.
- Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 Diabetes.
- Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 Diabetes.
- Challenges in developing endpoints for type 1 Diabetes intervention studies.
- Treatment of patients with new onset Type 1 Diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
- Towards a curative therapy in type 1 Diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass.
- Anti-CD3 mAbs for treatment of type 1 Diabetes.
- Continuous glucose monitoring: long live the revolution!
- Prevention of type 1 Diabetes: the time has come.
- A patient with Type B insulin resistance syndrome, responsive to immune therapy.
- RAGE: a journey from the complications of diabetes to Disorders of the nervous system - striking a fine balance between injury and repair.
- Drug insight: New immunomodulatory therapies in type 1 Diabetes.
- Islet transplantation for type 1 Diabetes--where should we go?
- Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of Type 1 diabe...
- Receptor for advanced glycation end products and the cardiovascular complications of Diabetes and beyond: lessons from AGEing.
- Visualizing pancreatic beta-cell mass With [11C]DTBZ.
- Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress.
- Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo.
- Type 1 Diabetes as a relapsing-remitting disease?
- Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and athero...
- RAGE: exacting a toll on the host in response to polymicrobial sepsis and Listeria monocytogenes.
- Receptor for AGE (RAGE): weaving tangled webs Within the inflammatory response.
Schools
Thomas Jefferson University
Temple University Hospital
University of Chicago
Conditions Treated
- Calcium Metabolism Disorders
- Diabetes Type 1
- Diabetes Type 2
- Diabetes With Renal Manifestations
- View All
Doctors Specialties
- Endocrinology
Accepted Insurances
Education
-
University of Chicago -
Temple University Hospital -
Jefferson Medical College
Drug Facts
| NPI NUMBER | 1083709463 | |
| NPPES Provider LastName | HEROLD | |
| NPPES Provider FirstName | KEVAN | |
| NPPES Provider ZIPCode | 06520 | |
| NPPES Provider State | CT | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 69.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083709463 |
| Last Name Of The Provider | HEROLD |
| First Name Of The Provider | KEVAN |
| View All |
Similar Doctors
|
|
Dr. Joan O. Cho, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barbara I. Gulanski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Terry C. Taylor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam B. Mayerson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Surani R. Fernando, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jasdev S. Gondal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sonia K. Caprio, MD
This Doctor is OpenDoctor Recommended.
|